Deals
O’Melveny has represented workforce software developer Sapho in its USD200 million sale to multinational software company Citrix Systems.
The addition of Sapho will expand Citrix’s software offerings to include Sapho’s leading micro app workforce productivity platforms.
Founded in 2014, Sapho is used by customers in all industries to streamline their internal workflows, enable smart decision-making, and increase employee effectiveness and engagement. Citrix is a leader in workplace software systems, with more than 400,000 organisations – including 98 per cent of the Fortune 500 – using Citrix solutions.
The O’Melveny team was led by partner and M&A partner and
Inflexion Private Equity has completed a minority investment in European LifeCare Group (ELCG), Europe’s largest provider of vaccinations. The investment is being made by Inflexion Enterprise Fund IV, Inflexion’s dedicated lower mid-market fund.
Founded in 1998, today ELCG has over 50 specialist clinics in Denmark and the UK where the company trades under a number of brands, including London Travel Clinic. ELCG also works for both the Danish and English NHS as a contracted service provider of immunisation programmes in schools and national influenza vaccination programmes. In 2018, ELCG is forecast to vaccinate approximately 400,000 individuals on behalf of the
FairMoney, a fair loan comparison website, has commenced its pre-series fundraising found of GBP1 million.
The funds raised will be used primarily for enhanced targeted customer marketing efforts, including machine intelligence, to provide customers with the very best and fairest deals for them. It will target the areas of the country which are most affected by sub-standard lending practices – many of which are building consumer debt and exacerbating poverty. In addition, following unique and exclusive research commissioned by FairMoney exploring Brits and their finances, the raise will fund even greater customer research to help focus services in the regions
ACProducts (acpi) is to acquire Elkay Wood Products Company (EWP), a manufacturer of kitchen and bath cabinetry.
EWP is a renowned manufacturer with an iconic brand portfolio including Medallion, Design-Craft, Yorktowne, Schuler, Medallion at Menards, MasterCraft, and American Cabinetry Collection.
The combined company will represent the most diverse and balanced cabinet company in North America. With an expansive portfolio across both framed and frameless product offerings, the combined company will be a leader in serving the dealer, direct-to-builder, and home centre channels. The combined plant network spans a national footprint with infrastructure to effectively serve cabinet buyers in all
The Riverside Company has signed a definitive agreement to sell its investment in Euromed Botanicals SA (Euromed) to Dermapharm Holding SE.
Barcelona-based Euromed provides standardised herbal extracts and natural active substances for the pharmaceutical, dietary supplement and cosmetic industries. The transaction is expected to close in the next few months upon receipt of antitrust approval.
Riverside invested in the company back in 2015. Euromed processes more than 5,000 tons of raw materials every year to produce high-quality extracts to meet the needs of more than 300 customers in 35 countries worldwide.
“Euromed’s already-premier brand and quality product
DIP Capital’s Disruption Investment Platform (DIP) Fund I has invested GBP1.5 million in wejo, a leading UK technology company which collates data from connected vehicles.
DIP Capital was established in February 2018 and focuses on investing in disruptive businesses. Founded and led by Riccardo Cirillo, DIP has a first fund of EUR40 million for deployment globally and is sponsored by Platina Partners, an independent European investment firm focusing on renewable energy and private equity.
DIP’s investment in wejo was part of a larger round that also included the participation of the majority of existing wejo investors. The investment will
FundRock Management Company (FundRock) has completed the acquisition of SEB Fund Services (SEB FS) from Skandinaviska Enskilda Banken AB (publ) (SEB).
The deal was first announced on 22 May and has concluded following regulatory approval from the Commission de Surveillance du Secteur Financier (CSSF).
SEB FS is offering third party management company services to Nordic asset managers with Luxembourg-based investment funds. The business in its entirety, including some 20 employees, is as of today transferred to FundRock.
“This move is part of our five year plan and provides a strong foundation to reach our goal of becoming
Audax Private Equity (Audax) and LLR Partners (LLR), in partnership with management, have completed the sale of Numotion to AEA Investors (AEA) and Numotion management.
Headquartered in Brentwood, TN, Numotion is a provider of Complex Rehab Technology (CRT), improving the lives of people with disabilities by enabling them to actively participate in everyday life. CRT is medically necessary, individually configured mobility products and services, including manual and power wheelchairs, designed to meet the unique medical and functional needs of individuals with significant disabilities and medical conditions to provide them with greater independence. Numotion serves over 250,000 customers across 140 locations
Camel-IDS, a VUB spin-off company developing cancer-targeted radio-pharmaceuticals, has secured EUR37 million in a Series A investment round led by V-Bio Ventures (Belgium) and Gimv (Belgium), joined by the co- lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel) and BioMedPartners (Switzerland). Existing investors also participated.
The proceeds will enable Camel-IDS to run a phase Ib/II trial with its lead program CAM-H2 targeting HER2-positive brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline.
Breast cancer patients with tumours that over-express HER2, a growth-promoting protein, can benefit from effective targeted treatments today, yet have a poor prognosis when
NOXXON Pharma, a biotechnology company focussed on improving cancer treatments by targeting the tumour microenvironment (TME), has secured an equity capital raise totalling EUR6.2 million, including USD5 million committed by lead investor, Acuitas Capital, LLC, a US based family office.
This equity capital raise meets the criteria to end YA II PN’s (Yorkville) ability to invest in NOXXON via the variable rate equity vehicle without the consent of NOXXON. Additionally, NOXXON has contractually committed not to use Yorkville or any other variable rate vehicles for two years, by which time the ability to pull tranches from the Yorkville vehicle will
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
